Multiple sclerosis is an inflammatory autoimmune disease, meaning the body attacks itself. The damage plays out in the central nervous system (brain and spinal cord), where the nerve endings and the ...
Roche’s star multiple sclerosis (MS) drug Ocrevus (ocrelizumab) infusion has been approved in Europe, the first and only approved disease-modifying drug for a debilitating form of the disease. EU ...
– 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to Ocrevus in open-label ...
Roche’s Phase III trial examining higher doses of intravenous (IV) Ocrevus (ocrelizumab) as a means of slowing disability progression in patients living with relapsing multiple sclerosis (MS) has not ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ ...
– 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study – ...
The U.S. Food and Drug Administration (FDA) approved Roche Holding AG’s multiple sclerosis (MS) drug Ocrevus Tuesday, making it the first U.S.-approved medicine for the primary progressive form of the ...
Roche’s much-anticipated multiple sclerosis drug ocrelizumab trounced a standard treatment, Rebif, in a new analysis of Phase III data, adding to competitive stats that could prove an edge in the ...
The Food and Drug Administration approved a new drug to treat multiple sclerosis Tuesday. The drug, called Ocrevus, is approved for use against the most common form of MS – the relapsing-remitting ...
– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...
75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label ...
Roche’s star multiple sclerosis (MS) drug Ocrevus (ocrelizumab) infusion has been approved in Europe, the first and only approved disease-modifying drug for a debilitating form of the disease. EU ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results